RT Journal Article
SR Electronic
T1 Pharmacological interventions for COVID-19: Protocol for a Rapid Living Systematic Review with network meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.02.20088823
DO 10.1101/2020.05.02.20088823
A1 Pinto, Ana Carolina Pereira Nunes
A1 da Rocha, Aline Pereira
A1 Milby, Keilla Martins
A1 Rocha-Filho, César Ramos
A1 de Assis Reis, Felipe Sebastião
A1 Junior, Nelson Carvas
A1 Civile, Vinicius Tassoni
A1 Santos, Rodolfo Rodrigo Pereira
A1 Trevisani, Giulia Fernandes Moça
A1 Ferla, Laura Jantsch
A1 Ramalho, Gabriel Sodré
A1 Puga, Maria Eduarda Santos
A1 Trevisani, Virgínia Fernandes Moça
A1 Atallah, Alvaro Nagib
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088823.abstract
AB CONTEXT AND OBJECTIVE Coronavirus disease 2019 (COVID-19) has emerged in China in December 2019 and rapidly spread. Although extraordinary efforts have been made on research regarding pharmacological interventions, none have proven effective. This is the protocol for a rapid living systematic review that aims to compare the effectiveness and safety of different pharmacological interventions for the treatment of COVID-19.METHODS rapid living systematic review methodology with Network Meta-Analysis following the recommendations of Cochrane Handbook. We will include randomized controlled trials (RCT) and quasi-RCTs that evaluate single and/or combined pharmacological interventions at any dose for the treatment of COVID-19. We will search PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), LILACS, Scopus and SciELO to identify potentially eligible studies. No language restrictions will be used in the selection. We will perform the critical appraisal of included studies with the Risk of Bias tool and the certainty of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCRD42020179818Funding StatementThis study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior‐Brasil (CAPES)‐ Finance Code 001Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article